What is the appropriate treatment for severe Morbihan disease in a 61‑year‑old man with Crohn’s disease who is on azathioprine and has only partially responded to isotretinoin and prednisone 20 mg tapering to 10 mg after one month?

Treatment Recommendation for Severe Morbihan Disease with Partial Response to Current Therapy

In this 61-year-old man with severe Morbihan disease and coexisting Crohn's disease who has only partially responded to isotretinoin and prednisone, the optimal next step is to add infliximab (combined with his existing azathioprine) while continuing isotretinoin and completing the prednisone taper.

Rationale for Anti-TNF Therapy

The patient's Crohn's disease is already being treated with azathioprine monotherapy, which represents suboptimal management for moderate-to-severe inflammatory bowel disease. British Society of Gastroenterology guidelines strongly recommend that combination therapy of infliximab with a thiopurine (azathioprine) is more effective than monotherapy for both induction and maintenance of remission in active Crohn's disease 1. The SONIC study demonstrated superior clinical remission and mucosal healing with combined infliximab and azathioprine versus either agent alone 1.

For the Morbihan disease component, while no guidelines specifically address this rare condition, the inflammatory pathophysiology suggests anti-TNF therapy may provide benefit. The patient has already demonstrated partial response to isotretinoin, indicating some disease modifiability, but requires additional immunosuppression given the severity and persistence of symptoms.

Specific Treatment Algorithm

Immediate Actions (Week 0-2):

1. Initiate infliximab: 5 mg/kg IV at weeks 0,2, and 6, then every 8 weeks 1, 2
2. Continue azathioprine: Maintain current dose (ensure 2-3 mg/kg/day if tolerated) 1
3. Continue isotretinoin: Maintain current dose through prednisone taper
4. Complete prednisone taper: Reduce from current 10 mg to discontinuation over 2-4 weeks 3

Monitoring at 8-12 Weeks:

Evaluate symptomatic response to anti-TNF induction therapy to determine need to modify treatment 3. Assess:

• Reduction in facial edema and erythema
• Crohn's disease activity (symptoms, inflammatory markers)
• Complete blood count (weekly initially, then monthly) 4
• Liver function tests 4

If Suboptimal Response at 8-12 Weeks:

Consider dose intensification of infliximab (increase to 10 mg/kg or shorten interval to every 6 weeks) 1. Therapeutic drug monitoring should inform dose optimization 3.

If Good Response:

Continue combination infliximab/azathioprine maintenance therapy indefinitely for Crohn's disease 1. Continue isotretinoin for Morbihan disease for at least 12-24 months based on case series showing sustained remission with long-term therapy 5, 6, 7.

Critical Safety Considerations

Infection Risk:

The combination of azathioprine, infliximab, and recent corticosteroids creates significant immunosuppression. Before initiating infliximab, perform purified protein derivative (PPD) skin testing to exclude latent tuberculosis 2. Monitor for serious infections including pneumonia, sepsis, tuberculosis, and opportunistic infections 2.

Hematologic Monitoring:

Complete blood counts with platelet counts must be performed weekly during the first month, twice monthly for months 2-3, then monthly 4. The patient is already on azathioprine, but adding infliximab increases infection risk and requires vigilant monitoring.

Drug Interactions:

Azathioprine with isotretinoin does not have documented interactions, but both can cause hepatotoxicity. Monitor liver enzymes monthly 4, 8.

Contraindications to Verify:

• No active infection
• No history of lymphoma or malignancy (increased risk with combination immunosuppression)
• Negative pregnancy test if applicable (isotretinoin is teratogenic) 8

Why Not Alternative Approaches?

Increasing prednisone dose: Canadian guidelines strongly recommend against using oral corticosteroids to maintain remission in Crohn's disease 3. Prolonged corticosteroid use carries significant morbidity (osteoporosis, infection, metabolic complications) without addressing the underlying inflammatory process 9, 10.

Switching from azathioprine to methotrexate: While methotrexate is an option for corticosteroid-dependent Crohn's disease 1, 3, the patient is already on azathioprine. The superior approach is adding infliximab to the existing azathioprine rather than switching immunomodulators, as combination therapy is proven more effective 1, 11.

Increasing isotretinoin dose alone: Case reports show isotretinoin efficacy for Morbihan disease at doses of 10-80 mg daily 5, 6, 12, 7, but the patient has already demonstrated only partial response. Additional immunosuppression is needed rather than simply increasing isotretinoin.

JAK inhibitors (tofacitinib): While case reports show promise for Morbihan disease 13, this would not address the Crohn's disease optimally. Infliximab has stronger evidence for Crohn's disease and may benefit both conditions.

Common Pitfalls to Avoid

1. Premature discontinuation of isotretinoin: Case series demonstrate that sustained remission of Morbihan disease requires 12-24 months of isotretinoin therapy 5, 7. Do not stop prematurely despite adding other agents.

2. Inadequate infection screening: Failure to screen for latent tuberculosis before infliximab is a critical error that can result in life-threatening reactivation 2.

3. Insufficient monitoring: The combination of three immunosuppressive agents requires more frequent monitoring than any single agent alone. Weekly CBC initially is mandatory 4.

4. Treating Morbihan disease in isolation: This patient has two inflammatory conditions. The treatment plan must address both simultaneously, and infliximab/azathioprine combination optimizes Crohn's disease management while potentially benefiting the Morbihan disease through anti-inflammatory effects.